Search research articles
Contact Us
Filters
Showing results (1-10 of 11) with videos related to
Page
of 2
Sort By:
Gene Regulation and Systems Biology
|
October 20, 2009
Letter to the editor: Does dicer expression affect shRNA processing?
Neil Senzer, Donald Rao, John Nemunaitis
Experimental Cell Research
|
October 22, 2003
Intraclonal plasticity for bone, smooth muscle, and adipocyte lineages in bone marrow stroma fibroblastoid cells
Norman S Wolf, Philip E Penn, Donald Rao, et al.
Scientific Reports
|
March 14, 2025
Exome sequencing shows same pattern of clonal tumor mutational burden, intratumor heterogenicity and clonal neoantigen between autologous tumor and Vigil product
David Willoughby, Ernest Bognar, Laura Stanbery, et al.
The Journal of Gene Medicine
|
May 26, 2026
In Vivo Assessment of dbDNA GNE<sup>wt</sup>/bi-shRNA-GNE<sup>M743T</sup> Lipoplex for GNE Myopathy: Improved Potency and Safety
Christopher M Jay, Fabienne Kerneis, Donald Rao, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
April 26, 2016
Three-year Follow up of GMCSF/bi-shRNA(furin) DNA-transfected Autologous Tumor Immunotherapy (Vigil) in Metastatic Advanced Ewing's Sarcoma
Maurizio Ghisoli, Minal Barve, Robert Mennel, et al.
Future Oncology (London, England)
|
March 24, 2025
Clinical characterization and therapeutic targeting of fusion genes in oncology
Susan Morand, Lauren Rager, Daniel Craig, et al.
Future Science OA
|
March 2, 2026
Preclinical assessment of GNE<sup>wt</sup>/bi-shRNA-GNE<sup>M743T</sup> lipoplex product development for GNE myopathy
Fabienne Kerneis, Christopher M Jay, Donald Rao, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society
|
March 2, 2024
Smart exosomes enhance PDAC targeted therapy
Justin F Creeden, Jonathan Sevier, Jian-Ting Zhang, et al.
JCO Precision Oncology
|
January 14, 2026
Gemogenovatucel-T Advantage in Clonal Tumor Mutation Burden-High Ovarian Cancer
Robert L Coleman, Rodney Rocconi, Bradley J Monk, et al.
Future Oncology (London, England)
|
August 5, 2024
Gemogenovatucel-T (Vigil): bi-shRNA plasmid-based targeted immunotherapy
John Nemunaitis, Laura Stanbery, Adam Walter, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 11) with videos related to
Sort By:
Page
of 2
Gene Regulation and Systems Biology
|
October 20, 2009
Letter to the editor: Does dicer expression affect shRNA processing?
Neil Senzer, Donald Rao, John Nemunaitis
Experimental Cell Research
|
October 22, 2003
Intraclonal plasticity for bone, smooth muscle, and adipocyte lineages in bone marrow stroma fibroblastoid cells
Norman S Wolf, Philip E Penn, Donald Rao, et al.
Scientific Reports
|
March 14, 2025
Exome sequencing shows same pattern of clonal tumor mutational burden, intratumor heterogenicity and clonal neoantigen between autologous tumor and Vigil product
David Willoughby, Ernest Bognar, Laura Stanbery, et al.
The Journal of Gene Medicine
|
May 26, 2026
In Vivo Assessment of dbDNA GNE<sup>wt</sup>/bi-shRNA-GNE<sup>M743T</sup> Lipoplex for GNE Myopathy: Improved Potency and Safety
Christopher M Jay, Fabienne Kerneis, Donald Rao, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
April 26, 2016
Three-year Follow up of GMCSF/bi-shRNA(furin) DNA-transfected Autologous Tumor Immunotherapy (Vigil) in Metastatic Advanced Ewing's Sarcoma
Maurizio Ghisoli, Minal Barve, Robert Mennel, et al.
Future Oncology (London, England)
|
March 24, 2025
Clinical characterization and therapeutic targeting of fusion genes in oncology
Susan Morand, Lauren Rager, Daniel Craig, et al.
Future Science OA
|
March 2, 2026
Preclinical assessment of GNE<sup>wt</sup>/bi-shRNA-GNE<sup>M743T</sup> lipoplex product development for GNE myopathy
Fabienne Kerneis, Christopher M Jay, Donald Rao, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society
|
March 2, 2024
Smart exosomes enhance PDAC targeted therapy
Justin F Creeden, Jonathan Sevier, Jian-Ting Zhang, et al.
JCO Precision Oncology
|
January 14, 2026
Gemogenovatucel-T Advantage in Clonal Tumor Mutation Burden-High Ovarian Cancer
Robert L Coleman, Rodney Rocconi, Bradley J Monk, et al.
Future Oncology (London, England)
|
August 5, 2024
Gemogenovatucel-T (Vigil): bi-shRNA plasmid-based targeted immunotherapy
John Nemunaitis, Laura Stanbery, Adam Walter, et al.
Page
of 2